 |
|
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
There has been some movement as of late with this stock. With the HUGE spread and the fact that the company was delisted I thought that this was just another Shell Scam. But after some exstensive D&D and a Few phone calls I have found out that even though it would seem that the Offices of HPFS have closed there doors and pulled the plug on the phone, THE Center for Special Immunology, Inc. {HPFS fully owns CSI}, is indeed a going concern there focus is..... CFIDS is believed to result from a genetic failing occurring in the immune response genes. This defect, when coupled with certain viral infections or other activating factors, leads to a state of chronic immune activation, which causes a variety of symptoms, including profound fatigue. CSI has developed treatment protocols for chronic fatigue patients, the goal of which is to re-balance the immune system or otherwise alleviate symptoms. Through its efforts in research and practical application, CSI has developed protocols for the treatment of HIV patients. These protocols specify the treatments and therapies to be provided to HIV patients, depending on the stage of the disease as determined by a multi-parametric evaluation of clinical status, viral activity and immunologic function. Treatment of HIV patients at CSI facilities by their affiliated physicians is offered in accordance with these protocols. CSI has also developed research protocols which govern the processes and record keeping practices to be followed in specified studies performed by CSI. These studies may be undertaken at CSI's initiative or in conjunction with a separate organization (e.g., a pharmaceutical company), which would typically finance the study and pay certain fees to CSI in return for conducting its portion of the clinical trial. CFIDS is believed to result from a genetic failing occurring in the immune DD on HPFS In December, 1991, the Company acquired 100% of Center for Special Immunology, Inc., a Delaware corporation ("CSI") and its subsidiaries which have since become the only operating businesses of the Company. CSI owns and operates an integrated health care delivery and clinical research system that includes a multi-state network, operating in 9 states, of primary care and clinical research facilities specializing in immune system disorders, consisting primarily of HIV, AIDS and Chronic Fatigue Immune Dysfunction Syndrome (CFIDS). The network also conducts multi-center trials in cooperation with biotechnology and pharmaceutical companies. CSI was founded in 1986 by William M. Reiter, M.D., FACP, and Paul J. Cimoch, M.D., FACP, who are both internationally recognized research physicians. Dr. Reiter is currently Chairman of the Board and Dr. Cimoch also currently serves on the Board. edgar-online.com hivinsite.ucsf.edu Center for Special Immunology - Irvine, Irvine, CA (714) 753-0670 Cimoch Center for Special Immunology - San Diego, San Diego, CA (619) 291-1122 Pearce Center Special Immunology - Chicago, , (312) 296-2400 Berger yp2.superpages.com yp1.superpages.com | ||||||||||||
|
|
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2020 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News |